Multiple GPRC5D Agents For Myeloma Raise Questions On Positioning

Bispecifics Could Be Better For More Vulnerable Patients

 
• By Alaric DeArment
Data for multiple GPRC5D programs were presented at ASH 2022 • Source: Shutterstock

More from Clinical Trials

More from R&D